FulvestrantA Review of its Use in the Management of Hormone Receptor-Positive Metastatic Breast Cancer in Postmenopausal Women

被引：0
|
作者：
Jamie D. Croxtall
Kate McKeage
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Tamoxifen; Postmenopausal Woman; Anastrozole; Exemestane; Fulvestrant;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Fulvestrant (Faslodex®) is an intramuscularly administered steroidal estrogen receptor antagonist that is devoid of any known estrogen agonist effects. It is indicated as second-line therapy for the treatment of postmenopausal women with hormone receptor-positive advanced breast cancer who have progressed following prior endocrine therapy.
引用
收藏
页码：363 / 380
页数：17
相关论文
共 50 条
  • [21] Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer
    Lippman, Marc
    LANCET ONCOLOGY, 2019, 20 (03): : 312 - 313
  • [22] What Is the Optimal Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer?
    Tung, Nadine
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1391 - 1397
  • [23] Adjuvant Endocrine Therapy of Perimenopausal and Recently Postmenopausal Women With Hormone Receptor-Positive Breast Cancer
    Pan, Kathy
    Chlebowski, Rowan T.
    CLINICAL BREAST CANCER, 2014, 14 (03) : 147 - 153
  • [24] Obesity and Postmenopausal Hormone Receptor-positive Breast Cancer: Epidemiology and Mechanisms
    Zuo, Qianying
    Band, Shoham
    Kesavadas, Mrinali
    Madak Erdogan, Zeynep
    ENDOCRINOLOGY, 2021, 162 (12)
  • [25] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ahrong Ham
    Min Hwan Kim
    Gun Min Kim
    Jee Hung Kim
    Jee Ye Kim
    Hyung Seok Park
    Seho Park
    Young Up Cho
    Byeong Woo Park
    Seung Il Kim
    Joohyuk Sohn
    Breast Cancer Research and Treatment, 2020, 183 : 107 - 116
  • [26] Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer
    Ham, Ahrong
    Kim, Min Hwan
    Kim, Gun Min
    Kim, Jee Hung
    Kim, Jee Ye
    Park, Hyung Seok
    Park, Seho
    Cho, Young Up
    Park, Byeong Woo
    Kim, Seung Il
    Sohn, Joohyuk
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (01) : 107 - 116
  • [27] A Pilot Study of Estradiol Followed by Exemestane for Reversing Endocrine Resistance in Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer
    Chalasani, Pavani
    Stopeck, Alison
    Clarke, Kathryn
    Livingston, Robert
    ONCOLOGIST, 2014, 19 (11): : 1127 - 1128
  • [28] Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer
    Montemurro, Filippo
    Rossi, Valentina
    Geuna, Elena
    Valabrega, Giorgio
    Martinello, Rossella
    Milani, Andrea
    Aglietta, Massimo
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (15) : 2143 - 2156
  • [29] Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
    Yardley, Denise A.
    BREAST CANCER-TARGETS AND THERAPY, 2016, 8 : 73 - 82
  • [30] Sacituzumab Govitecan in Hormone Receptor-Positive Metastatic Breast Cancer Reply
    Rugo, Hope S.
    Bardia, Aditya
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (08) : 1631 - +
12345